Sacrospinous Hysteropexy With Mesh vs Vaginal Hysterectomy for Treatment of Uterovaginal Prolapse
JAMA Surgery · 01.08.2026 · 161 (8) · 764
DOI: 10.1001/jamasurg.2026.2263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, erschienen am 01.08.2026. Verfasst von Charles W Nager und 11 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics, Gynecology, and Reproductive Sciences, UC San Diego Health, San Diego, California. Hauptthemen laut MEDLINE: Uterine Prolapse, Surgical Mesh, Hysterectomy, Vaginal, Gynecologic Surgical Procedures. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Importance Vaginal hysterectomy with suture apical suspension (hysterectomy) is commonly performed for uterovaginal prolapse, and a vaginal sacrospinous hysteropexy with graft (hysteropexy) is a uterine-sparing alternative. Ten-year outcomes for prolapse surgeries are rarely reported.
Objective
To compare the efficacy and adverse events of these 2 procedures over 10 years. Design, Setting, and Participants At 9 clinical sites in the US Pelvic Floor Disorders Network, postmenopausal women with symptomatic uterovaginal prolapse were enrolled in a multisite superiority randomized clinical trial between April 2013 and February 2015. Study data were analyzed from February 2018 to November 2025.
Interventions
Women were originally randomized to vaginal mesh hysteropexy or to vaginal hysterectomy with uterosacral ligament suspension. Participants had 5 years of masked follow-up at 6-month intervals followed by an extended unmasked annual follow-up from 6 to 10 years. Main Outcomes and Measures The primary treatment failure composite outcome (retreatment of prolapse, prolapse beyond the hymen, or prolapse symptoms) was evaluated with time-to-failure models. Secondary outcomes included individual anatomic Pelvic Organ Prolapse Quantification measures, bothersome symptoms measured by validated questionnaires, complications and adverse events.
Results
A total of 183 participants (mean [SD] age, 66 [7] years) were randomized, and 175 were included in the intention-to-treat analysis after ineligibility exclusions (88 hysteropexy group and 87 hysterectomy group), 112 of whom (64%; 55 hysteropexy group and 57 hysterectomy group) participated in the 6- to 10-year follow-up extension. There were fewer failures for hysteropexy (35 of 88 [40%]) compared with hysterectomy (46 of 87 [53%]) through 10 years. Time-to-failure analysis showed lower failure risk in hysteropexy (adjusted hazard ratio, 0.64; 95% CI, 0.41-1.00; P = .05). Both groups had sustained improvements in patient reported outcomes with no group differences demonstrated in patient-reported prolapse, urinary, or bowel symptoms, sexual function, dyspareunia, or clinically important complications. Conclusions and Relevance Results show that vaginal mesh hysteropexy continued to have a lower composite failure rate through 10 years than vaginal hysterectomy with uterosacral ligament suspension, although an expected increase in durability over the native tissue procedure in years 6 to 10 was not observed. Both procedures are reasonable options for patients. If available, hysteropexy with mesh augmentation for patients who desire uterine preservation is a low risk and effective option. Trial Registration ClinicalTrials.gov Identifier: NCT01802281
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Obstetrics, Gynecology, and Reproductive Sciences, UC San Diego Health, San Diego, California.
- Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
- Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham.
- Department of Obstetrics and Gynecology, Women & Infants Hospital of Rhode Island, Providence.
- Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque.
- Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Förderung
- NICHD NIH HHS
Zitieren
APA
Nager, C. W., Visco, A. G., Richter, H. E., Rardin, C. R., Meriwether, K., Harvie, H. S., Zyczynski, H. M., Paraiso, M. F. R., Mazloomdoost, D., Sridhar, A., Thomas, S., & Eunice Kennedy Shriver NICHD Pelvic Floor Disorders Network (2026). Sacrospinous Hysteropexy With Mesh vs Vaginal Hysterectomy for Treatment of Uterovaginal Prolapse. JAMA Surgery, 161(8), 764. https://doi.org/10.1001/jamasurg.2026.2263
Vancouver
Nager CW, Visco AG, Richter HE, Rardin CR, Meriwether K, Harvie HS, et al. Sacrospinous Hysteropexy With Mesh vs Vaginal Hysterectomy for Treatment of Uterovaginal Prolapse. JAMA Surgery. 2026;161(8):764. doi:10.1001/jamasurg.2026.2263
BibTeX
@article{Nager2026,
author = {Nager, Charles W and Visco, Anthony G and Richter, Holly E and Rardin, Charles R and Meriwether, Kate and Harvie, Heidi S and Zyczynski, Halina M and Paraiso, Marie Fidela R and Mazloomdoost, Donna and Sridhar, Amaanti and Thomas, Sonia and Eunice Kennedy Shriver NICHD Pelvic Floor Disorders Network, Eunice Kennedy Shriver NICHD Pelvic Floor Disorders Network},
title = {Sacrospinous Hysteropexy With Mesh vs Vaginal Hysterectomy for Treatment of Uterovaginal Prolapse},
journal = {JAMA Surgery},
year = {2026},
volume = {161},
number = {8},
pages = {764},
doi = {10.1001/jamasurg.2026.2263}
}
EUVIMED